Epizyme sank almost 20% since their last earnings report, but recent developments show positive data from one of its keynote drugs, Tazemetostat
Other industry list-toppers included MiMedx, Cytokinetics, C.R. Bard, and Spectrum.
The settlement provides Mylan with global licenses for its trastuzumab product.
Here is a round-up of the news from Europe.